Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, Thomas-Schoemann A, Chevrier R, Daouphars M, Madelaine I, Pourroy B, Tournamille JF, Astier A, Ranchon F, Cazin JL, Bardin C, Rioufol C. Slimano F, et al. Among authors: thomas schoemann a. Cancer Treat Rev. 2020 Aug;88:102063. doi: 10.1016/j.ctrv.2020.102063. Epub 2020 Jun 23. Cancer Treat Rev. 2020. PMID: 32623296 Free PMC article. Review.
Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Thomas-Schoemann A, et al. Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041628 Review.
Bystander effect of vinorelbine alters antitumor immune response.
Thomas-Schoemann A, Lemare F, Mongaret C, Bermudez E, Chéreau C, Nicco C, Dauphin A, Weill B, Goldwasser F, Batteux F, Alexandre J. Thomas-Schoemann A, et al. Int J Cancer. 2011 Sep 15;129(6):1511-8. doi: 10.1002/ijc.25813. Epub 2011 Apr 1. Int J Cancer. 2011. PMID: 21128224 Free article.
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F. Boudou-Rouquette P, et al. Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1433-1444. doi: 10.1080/17425255.2016.1225038. Epub 2016 Aug 24. Expert Opin Drug Metab Toxicol. 2016. PMID: 27556889 Review.
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.
Bellesoeur A, Gataa I, Jouinot A, Mershati SE, Piketty AC, Tlemsani C, Balakirouchenane D, Monribot A, Vidal M, Batista R, de Percin S, Villeminey C, Alexandre J, Goldwasser F, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A. Bellesoeur A, et al. Among authors: thomas schoemann a. Cancer Chemother Pharmacol. 2021 Oct;88(4):741-751. doi: 10.1007/s00280-021-04311-4. Epub 2021 Jul 24. Cancer Chemother Pharmacol. 2021. PMID: 34304283
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F. Huillard O, et al. Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Expert Opin Drug Saf. 2014. PMID: 24693873 Review.
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
Bonnet C, Boudou-Rouquette P, Azoulay-Rutman E, Huillard O, Golmard JL, Carton E, Noé G, Vidal M, Orvoen G, Chah Wakilian A, Villeminey C, Blanchet B, Alexandre J, Goldwasser F, Thomas-Schoemann A. Bonnet C, et al. Cancer Chemother Pharmacol. 2017 May;79(5):1051-1055. doi: 10.1007/s00280-017-3291-z. Epub 2017 Mar 30. Cancer Chemother Pharmacol. 2017. PMID: 28361167
51 results